BR112022005026A2 - Conjugados terapêuticos - Google Patents
Conjugados terapêuticosInfo
- Publication number
- BR112022005026A2 BR112022005026A2 BR112022005026A BR112022005026A BR112022005026A2 BR 112022005026 A2 BR112022005026 A2 BR 112022005026A2 BR 112022005026 A BR112022005026 A BR 112022005026A BR 112022005026 A BR112022005026 A BR 112022005026A BR 112022005026 A2 BR112022005026 A2 BR 112022005026A2
- Authority
- BR
- Brazil
- Prior art keywords
- therapeutic conjugates
- conjugates
- therapeutic
- administering
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962902554P | 2019-09-19 | 2019-09-19 | |
| US202063078055P | 2020-09-14 | 2020-09-14 | |
| PCT/US2020/051491 WO2021055747A1 (en) | 2019-09-19 | 2020-09-18 | Therapeutic conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022005026A2 true BR112022005026A2 (pt) | 2022-06-21 |
Family
ID=74883745
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022005026A BR112022005026A2 (pt) | 2019-09-19 | 2020-09-18 | Conjugados terapêuticos |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US20220387603A1 (https=) |
| EP (1) | EP4031143B1 (https=) |
| JP (1) | JP7810640B2 (https=) |
| KR (1) | KR20220079866A (https=) |
| CN (2) | CN120789282A (https=) |
| AU (1) | AU2020349543A1 (https=) |
| BR (1) | BR112022005026A2 (https=) |
| CA (1) | CA3154079A1 (https=) |
| CL (1) | CL2022000665A1 (https=) |
| CO (1) | CO2022003703A2 (https=) |
| DK (1) | DK4031143T3 (https=) |
| ES (1) | ES3043134T3 (https=) |
| IL (1) | IL291486B1 (https=) |
| MX (1) | MX2022003217A (https=) |
| PE (1) | PE20230091A1 (https=) |
| PH (1) | PH12022550494A1 (https=) |
| TW (1) | TWI870468B (https=) |
| WO (1) | WO2021055747A1 (https=) |
| ZA (1) | ZA202203201B (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220079866A (ko) | 2019-09-19 | 2022-06-14 | 토투스 메디신스 아이엔씨. | 치료 접합체 |
| WO2022198024A1 (en) * | 2021-03-18 | 2022-09-22 | Totus Medicines Inc. | Therapeutic conjugates |
| WO2023183936A2 (en) * | 2022-03-24 | 2023-09-28 | Totus Medicines Inc. | Combination therapy of a pi3k inhibitor and kras inhibitor and methods of use thereof |
| AU2023240100A1 (en) | 2022-03-24 | 2024-10-03 | Totus Medicines Inc. | Crystalline forms and salts of a pi3k inhibitor and methods of making and methods of use thereof |
| AU2023249795A1 (en) | 2022-04-08 | 2024-10-17 | Shy Therapeutics, Llc | Compounds that interact with ras superfamily proteins for treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
| WO2024086664A2 (en) * | 2022-10-18 | 2024-04-25 | Totus Medicines Inc. | Covalent inhibitors of wild-type and mutant pi3k and method of uses thereof |
| WO2024220380A2 (en) * | 2023-04-16 | 2024-10-24 | Totus Medicines Inc. | Pi3k assays and probe compounds therein |
| EP4704841A1 (en) | 2023-05-05 | 2026-03-11 | Eli Lilly and Company | Imlunestrant or salts thereof for use in treating and preventing central nervous system (cns) metastases in subjects having er+ breast cancer |
| CN117126164B (zh) * | 2023-08-30 | 2024-09-27 | 山东轩硕医药科技有限公司 | 一种吡咯并三嗪类化合物，其制备方法及用途 |
| WO2025072796A1 (en) * | 2023-09-27 | 2025-04-03 | Totus Medicines Inc. | Pharmaceutical compositions and methods of use thereof |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5585245A (en) | 1994-04-22 | 1996-12-17 | California Institute Of Technology | Ubiquitin-based split protein sensor |
| US6342345B1 (en) | 1997-04-02 | 2002-01-29 | The Board Of Trustees Of The Leland Stanford Junior University | Detection of molecular interactions by reporter subunit complementation |
| US6982265B1 (en) | 1999-05-21 | 2006-01-03 | Bristol Myers Squibb Company | Pyrrolotriazine inhibitors of kinases |
| US7306631B2 (en) | 2004-03-30 | 2007-12-11 | The Procter & Gamble Company | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof |
| WO2007035428A1 (en) | 2005-09-15 | 2007-03-29 | Bristol-Myers Squibb Company | Met kinase inhibitors |
| WO2009023179A2 (en) | 2007-08-10 | 2009-02-19 | Genelabs Technologies, Inc. | Nitrogen containing bicyclic chemical entities for treating viral infections |
| ES2660418T3 (es) * | 2008-07-16 | 2018-03-22 | Pharmacyclics Llc | Inhibidores de la tirosina quinasa de Bruton para el tratamiento de tumores sólidos |
| US20100204265A1 (en) | 2009-02-09 | 2010-08-12 | Genelabs Technologies, Inc. | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections |
| EP2475375A4 (en) * | 2009-09-09 | 2013-02-20 | Avila Therapeutics Inc | PI3 KINASE INHIBITORS AND USES THEREOF |
| EP2526102B1 (en) | 2010-01-22 | 2017-03-08 | Fundación Centro Nacional de Investigaciones Oncológicas Carlos III | Inhibitors of PI3 kinase |
| US20130131057A1 (en) | 2010-05-13 | 2013-05-23 | Centro Nacional De Investigaciones Oncologicas (Cnio | New bicyclic compounds as pi3-k and mtor inhibitors |
| AU2011258005A1 (en) | 2010-05-28 | 2013-01-17 | Biocryst Pharmaceuticals, Inc. | Heterocyclic compounds as Janus kinase inhibitors |
| US20120231963A1 (en) | 2011-03-10 | 2012-09-13 | Raybiotech, Inc, | Biotin-label-based antibody array for high-content profiling of protein expression |
| CA2836449C (en) * | 2011-05-17 | 2021-04-27 | The Regents Of The University Of California | Kinase inhibitors |
| EP2524918A1 (en) | 2011-05-19 | 2012-11-21 | Centro Nacional de Investigaciones Oncológicas (CNIO) | Imidazopyrazines derivates as kinase inhibitors |
| US9724352B2 (en) * | 2012-05-31 | 2017-08-08 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Pyrrolo[2,1-F[1,2,4]triazine compounds, preparation methods and applications thereof |
| CN103450204B (zh) * | 2012-05-31 | 2016-08-17 | 中国科学院上海药物研究所 | 吡咯[2，1-f][1，2，4]并三嗪类化合物，其制备方法及用途 |
| CN102675323B (zh) | 2012-06-01 | 2014-04-09 | 南京药石药物研发有限公司 | 吡咯并[2,1-f][1,2,4]三嗪衍生物及其抗肿瘤用途 |
| KR102420322B1 (ko) | 2014-06-17 | 2022-07-13 | 키에시 파르마슈티시 엣스. 피. 에이. | 포스포이노시타이드 3-키나아제 억제제로서 인돌리진 유도체 |
| ES2771926T3 (es) * | 2014-09-13 | 2020-07-07 | Novartis Ag | Terapias de combinación |
| WO2017004134A1 (en) | 2015-06-29 | 2017-01-05 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| CN109111447A (zh) * | 2017-06-23 | 2019-01-01 | 中国科学院上海药物研究所 | 7-位取代吡咯并三嗪类化合物或其药学上可用的盐，及其制备方法和用途 |
| US12291533B2 (en) | 2017-08-02 | 2025-05-06 | Northwestern University | Substituted fused pyrimidine compounds and uses thereof |
| WO2019113523A1 (en) | 2017-12-08 | 2019-06-13 | Ashok Bajji | Compounds and therapeutic uses thereof |
| CN109081905A (zh) | 2018-08-03 | 2018-12-25 | 浩力森涂料（上海）有限公司 | 水性环氧固化剂及其制备方法 |
| WO2020052772A1 (en) | 2018-09-13 | 2020-03-19 | Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) | Modulation of trf1 for brain cancer treatment |
| WO2020243457A1 (en) | 2019-05-29 | 2020-12-03 | Viogen Biosciences, Llc | Compounds and therapeutic uses thereof |
| KR20220079866A (ko) | 2019-09-19 | 2022-06-14 | 토투스 메디신스 아이엔씨. | 치료 접합체 |
| EP4165045A4 (en) | 2020-06-05 | 2024-07-03 | Monash University | DOUBLE KINASE-BROMODOMAIN INHIBITORS |
| US20230285498A1 (en) | 2020-08-07 | 2023-09-14 | City Of Hope | Treatments for cancers having kras mutations |
| WO2022198024A1 (en) | 2021-03-18 | 2022-09-22 | Totus Medicines Inc. | Therapeutic conjugates |
| WO2023183936A2 (en) | 2022-03-24 | 2023-09-28 | Totus Medicines Inc. | Combination therapy of a pi3k inhibitor and kras inhibitor and methods of use thereof |
| AU2023240100A1 (en) | 2022-03-24 | 2024-10-03 | Totus Medicines Inc. | Crystalline forms and salts of a pi3k inhibitor and methods of making and methods of use thereof |
-
2020
- 2020-09-18 KR KR1020227012813A patent/KR20220079866A/ko active Pending
- 2020-09-18 BR BR112022005026A patent/BR112022005026A2/pt not_active IP Right Cessation
- 2020-09-18 US US17/642,945 patent/US20220387603A1/en active Pending
- 2020-09-18 MX MX2022003217A patent/MX2022003217A/es unknown
- 2020-09-18 DK DK20865745.2T patent/DK4031143T3/da active
- 2020-09-18 PE PE2022000435A patent/PE20230091A1/es unknown
- 2020-09-18 EP EP20865745.2A patent/EP4031143B1/en active Active
- 2020-09-18 AU AU2020349543A patent/AU2020349543A1/en active Pending
- 2020-09-18 TW TW109132462A patent/TWI870468B/zh active
- 2020-09-18 JP JP2022516684A patent/JP7810640B2/ja active Active
- 2020-09-18 ES ES20865745T patent/ES3043134T3/es active Active
- 2020-09-18 WO PCT/US2020/051491 patent/WO2021055747A1/en not_active Ceased
- 2020-09-18 CA CA3154079A patent/CA3154079A1/en active Pending
- 2020-09-18 CN CN202510512926.7A patent/CN120789282A/zh active Pending
- 2020-09-18 CN CN202080074001.4A patent/CN114599366B/zh active Active
- 2020-09-18 PH PH1/2022/550494A patent/PH12022550494A1/en unknown
-
2022
- 2022-03-14 US US17/694,592 patent/US11484597B2/en active Active
- 2022-03-17 ZA ZA2022/03201A patent/ZA202203201B/en unknown
- 2022-03-18 CL CL2022000665A patent/CL2022000665A1/es unknown
- 2022-03-18 IL IL291486A patent/IL291486B1/en unknown
- 2022-03-28 CO CONC2022/0003703A patent/CO2022003703A2/es unknown
- 2022-09-28 US US17/955,182 patent/US12029791B2/en active Active
-
2024
- 2024-07-03 US US18/763,741 patent/US20240366771A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN120789282A (zh) | 2025-10-17 |
| CA3154079A1 (en) | 2021-03-25 |
| CN114599366B (zh) | 2025-05-09 |
| JP2022548135A (ja) | 2022-11-16 |
| TWI870468B (zh) | 2025-01-21 |
| US20240366771A1 (en) | 2024-11-07 |
| US20220211855A1 (en) | 2022-07-07 |
| US20230096658A1 (en) | 2023-03-30 |
| MX2022003217A (es) | 2022-06-29 |
| IL291486A (en) | 2022-05-01 |
| US12029791B2 (en) | 2024-07-09 |
| KR20220079866A (ko) | 2022-06-14 |
| CL2022000665A1 (es) | 2022-10-28 |
| ES3043134T3 (en) | 2025-11-24 |
| EP4031143A4 (en) | 2023-11-01 |
| CO2022003703A2 (es) | 2022-07-08 |
| IL291486B1 (en) | 2026-03-01 |
| US11484597B2 (en) | 2022-11-01 |
| AU2020349543A1 (en) | 2022-03-24 |
| EP4031143A1 (en) | 2022-07-27 |
| EP4031143B1 (en) | 2025-07-30 |
| DK4031143T3 (da) | 2025-10-13 |
| JP7810640B2 (ja) | 2026-02-03 |
| WO2021055747A1 (en) | 2021-03-25 |
| PE20230091A1 (es) | 2023-01-16 |
| US20220387603A1 (en) | 2022-12-08 |
| CN114599366A (zh) | 2022-06-07 |
| PH12022550494A1 (en) | 2023-02-27 |
| TW202126307A (zh) | 2021-07-16 |
| ZA202203201B (en) | 2023-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022005026A2 (pt) | Conjugados terapêuticos | |
| PH12020500240A1 (en) | Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies | |
| CY1123884T1 (el) | Αντισωματα enanti-cd123 και συζευγματα και παραγωγα αυτων | |
| AU2018236742B2 (en) | Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same | |
| ZA202001564B (en) | Anti- folate receptor alpha antibody conjugates and their uses | |
| BR112019012796A2 (pt) | proteínas de ligação ao antígeno antineuropilina e métodos de uso das mesmas | |
| BR112021025720A2 (pt) | Conjugados anticorpo-fármaco de fator antitecido e métodos relacionados | |
| BR112022002720A2 (pt) | Formulações de conjugados de benzazepinas e usos das mesmas | |
| CY1119454T1 (el) | Αντισωματα εναντι cd38 για τη θεραπεια του πολλαπλου μυελωματος | |
| BR112017019300A2 (pt) | conjugado de fórmula genérica ama - l - x - s - ab, método para sintetizar um conjugado de fórmula genérica ama - l - x - s - ab, kit, método para sintetizar o composto ama - l - x', composição farmacêutica e método para tratar uma doença associada a células que apresentam um alvo | |
| CY1119219T1 (el) | Anti-ceacam5 αντισωματα και χρησεις αυτων | |
| MX350200B (es) | Anticuerpos humanos y conjugados de anticuerpo-farmaco contra cd74. | |
| BR112022000337A2 (pt) | Conjugados de peptídeos de citotoxinas como terapêuticos | |
| MX2016001236A (es) | Anticuerpos anti-fgfr2iiib afucosilados. | |
| MX2017003246A (es) | Macropinocitosis de anticuerpos anti-cd46 humanos y agentes terapeuticos dirigidos contra el cancer. | |
| UA118332C2 (uk) | Білок, що зв'язує антиген cd27l | |
| PE20170903A1 (es) | Conjugados de farmacos con anticuerpos anti-cdh6 | |
| BR112023002116A2 (pt) | Proteínas que se ligam a nkg2d, cd16 e egfr | |
| BR112017018778A2 (pt) | conjugados anticorpo-fármaco à base de criptoficina com ligantes autodegradantes inovadores | |
| AU2017250507A8 (en) | Methods of treatment using chlorotoxin conjugates | |
| CL2018000131A1 (es) | Inmunoconjugados de il22 | |
| BR112015004515A2 (pt) | composição imunogênica | |
| MX2020005473A (es) | Anticuerpos humanizados que se dirigen al factor tisular humano. | |
| BR112022005465A2 (pt) | Conjugados de proteína-macromolécula e métodos de uso dos mesmos | |
| GT201300047A (es) | Tratamiento de hipertension y/o prevencion o tratamiento de insuficiencia cardiaca en un mamifero que recibe terapia anti-coagulante |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2846 DE 22-07-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |